{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:11Z","timestamp":1753891751008,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The pathogenesis of follicular lymphoma is a multi-step process, in which chromosomal translocation between immunoglobulin heavy chain (IgH) and anti-apoptotic B-cell lymphoma 2 (BCL2), namely IgH-BCL2, is an earliest step, followed by other genetic\/genomic alterations including but not limited to mutation of CREB binding protein (CREBBP). MHC class II transactivator (CIITA) is a transcription regulator responsible for expression of MHC class II molecules including HLA-DR in human. We report herein a novel fusion gene involving CIITA and CREBBP in a patient with a low-grade follicular lymphoma (FL) but with high Ki-67 proliferation index. In addition, our patient also harbors CREBBP mutation. Together, we postulate that total loss of CREBBP function may contribute, in part, to the lymphoma genesis. Furthermore, this patient has addition rare (TBL1XR1-TP63) and common (IgH-BCL2) chromosomal translocations and multiple mutations including <jats:italic>BCL2, BRAF, MUTYH<\/jats:italic>, and <jats:italic>STAT6<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fonc.2021.620435","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:21:08Z","timestamp":1615357268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Huan-You","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan S.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Mulroney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1534\/genetics.110.120683","article-title":"Different aneuploidies arise from the same bridge-induced chromosomal translocation event in Saccharomyces cerevisiae","volume":"186","author":"Rossi","year":"2010","journal-title":"Genetics."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9703","DOI":"10.1073\/pnas.0800464105","article-title":"Cellular and molecular effects of non-reciprocal chromosome translocations in Saccharomyces cerevisiae","volume":"105","author":"Nikitin","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2141.1999.01377.x","article-title":"The AML-ETO chimeric transcription factor in acute myeloid leukemia: biology and clinical significance","volume":"106","author":"Downing","year":"1999","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fonc.2017.00231","article-title":"Bridge-induced translocation between NUP145 and TOP2 yeast genes modles the genetic fusion between the human orthologs associated with acute myeloid leukemia","volume":"7","author":"Tosato","year":"2017","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ajcp\/103.4.472","article-title":"Comparison of cytogenetic analysis, southern analysis and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma","volume":"103","author":"Horsman","year":"1995","journal-title":"Am J Clin Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1073\/pnas.83.9.2984","article-title":"Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma","volume":"83","author":"Pelicci","year":"1986","journal-title":"Prod Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.4049\/jimmunol.169.9.5078","article-title":"Modulations of gene expression by the MHC class II transactivator","volume":"169","author":"Nagarajan","year":"2002","journal-title":"J Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/emboj\/16.10.2851","article-title":"Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promotersof the transactivator CIITA","volume":"16","author":"Muhlethaler-Mottet","year":"1997","journal-title":"EMBO J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1023\/B:JOCI.0000018068.37899.6d","article-title":"Persistence of MHC DR non-expression on swine cells by introduction of a mutated MHC class II transactivator gene: a comparison with the effect induced by antisense RNA","volume":"24","author":"Ou","year":"2004","journal-title":"J Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/gcc.10174","article-title":"t(10;16)(p22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia","volume":"36","author":"Vizmanos","year":"2003","journal-title":"Genes Chromosomes Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood.V96.3.808","article-title":"The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies","volume":"96","author":"Willis","year":"2000","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ncb3597","article-title":"Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors","volume":"19","author":"Horton","year":"2017","journal-title":"Nat Cell Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2018-03-837039","article-title":"CREBBP gene mutations are frequently detected in in situ follicular neoplasia","volume":"132","author":"Schmidt","year":"2018","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0360-3016(90)90546-V","article-title":"Cytogenetic effects of radiotherapy: frequency and types of chromosome aberrations","volume":"19","author":"Barrios","year":"1990","journal-title":"Int J Radiot Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1182\/blood-2012-02-414441","article-title":"TBL1XR1-TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma","volume":"119","author":"Scott","year":"2012","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2159-8290.CD-19-0029","article-title":"Gly101Val BCL2 mutation: one step closer to understanding Venetoclax resistance in CLL","volume":"3","author":"Thangavadivel","year":"2019","journal-title":"Cancer Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ajh.24701","article-title":"BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab","volume":"92","author":"Heut","year":"2017","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.620435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:21:10Z","timestamp":1615357270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.620435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":21,"alternative-id":["10.3389\/fonc.2021.620435"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.620435","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"article-number":"620435"}}